These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 17632094)

  • 1. Acrolein inactivates paraoxonase 1: changes in free acrolein levels after hemodialysis correlate with increases in paraoxonase 1 activity in chronic renal failure patients.
    Gugliucci A; Lunceford N; Kinugasa E; Ogata H; Schulze J; Kimura S
    Clin Chim Acta; 2007 Sep; 384(1-2):105-12. PubMed ID: 17632094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance.
    Gugliucci A; Mehlhaff K; Kinugasa E; Ogata H; Hermo R; Schulze J; Kimura S
    Clin Chim Acta; 2007 Feb; 377(1-2):213-20. PubMed ID: 17118352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum paraoxonase activity in uremic predialysis and hemodialysis patients.
    Dirican M; Akca R; Sarandol E; Dilek K
    J Nephrol; 2004; 17(6):813-8. PubMed ID: 15593056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.
    Aviram M; Rosenblat M; Bisgaier CL; Newton RS; Primo-Parmo SL; La Du BN
    J Clin Invest; 1998 Apr; 101(8):1581-90. PubMed ID: 9541487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of nandrolone decanonate on paraoxonase activity in hemodialysis patients.
    Ghorbanihaghjo A; Argani H; Rahbaninoubar M; Rashtchizadeh N
    Clin Biochem; 2005 Dec; 38(12):1076-80. PubMed ID: 16153628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paraoxonase enzyme activity is enhanced by zinc supplementation in hemodialysis patients.
    Rahimi-Ardabili B; Argani H; Ghorbanihaghjo A; Rashtchizadeh N; Naghavi-Behzad M; Ghorashi S; Nezami N
    Ren Fail; 2012; 34(9):1123-8. PubMed ID: 22950600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relation between paraoxonase activity, other HDL components and inflammatory state in hemodialyzed patients].
    González AI; Brites F; Elbert A; Gómez-Rosso L; Berg G; Wikinski R; Schreier L
    Medicina (B Aires); 2010; 70(6):508-12. PubMed ID: 21163737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of homocysteinylation on human high-density lipoproteins: a correlation with paraoxonase activity.
    Ferretti G; Bacchetti T; Marotti E; Curatola G
    Metabolism; 2003 Feb; 52(2):146-51. PubMed ID: 12601623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidative stress and high-density lipoprotein function in Type I diabetes and end-stage renal disease.
    Kalogerakis G; Baker AM; Christov S; Rowley KG; Dwyer K; Winterbourn C; Best JD; Jenkins AJ
    Clin Sci (Lond); 2005 Jun; 108(6):497-506. PubMed ID: 15634192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia.
    Marsillach J; Martínez-Vea A; Marcas L; Mackness B; Mackness M; Ferré N; Joven J; Camps J
    Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):347-9. PubMed ID: 17324148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of heparin and dalteparin on oxidative stress during hemodialysis in patients with end-stage renal disease.
    Nassiri AA; Hakemi MS; Soulati M; Marashian M; Rahbar K; Azizi F
    Iran J Kidney Dis; 2009 Jul; 3(3):162-7. PubMed ID: 19617666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paraoxonase 1 arylesterase activity and mass are reduced and inversely related to C-reactive protein in patients on either standard or home nocturnal hemodialysis.
    Kannampuzha J; Darling PB; Maguire GF; Donnelly S; McFarlane P; Chan CT; Connelly PW
    Clin Nephrol; 2010 Feb; 73(2):131-8. PubMed ID: 20129020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum paraoxonase levels in gastric cancer.
    Akçay MN; Yilmaz I; Polat MF; Akçay G
    Hepatogastroenterology; 2003 Dec; 50 Suppl 2():cclxxiii-cclxxv. PubMed ID: 15244199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum paraoxonase levels in pancreatic cancer.
    Akçay MN; Polat MF; Yilmaz I; Akçay G
    Hepatogastroenterology; 2003 Dec; 50 Suppl 2():ccxxv-ccxxvii. PubMed ID: 15244186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols.
    Nishio E; Watanabe Y
    Biochem Biophys Res Commun; 1997 Jul; 236(2):289-93. PubMed ID: 9240427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol.
    Bergheanu SC; Van Tol A; Dallinga-Thie GM; Liem A; Dunselman PH; Van der Bom JG; Jukema JW
    Curr Med Res Opin; 2007 Sep; 23(9):2235-40. PubMed ID: 17692153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum paraoxonase/arylesterase activities in phenylketonuric patients on diet.
    Schulpis KH; Bartzeliotou A; Tsakiris S; Gounaris A; Papassotiriou I
    Eur J Clin Nutr; 2007 Jun; 61(6):803-8. PubMed ID: 17203019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Serum Paraoxonase/Arylesterase Activity With All-Cause Mortality in Maintenance Hemodialysis Patients.
    Suematsu Y; Goto M; Park C; Nunes ACF; Jing W; Streja E; Rhee CM; Cruz S; Kashyap ML; Vaziri ND; Narayanaswami V; Kalantar-Zadeh K; Moradi H
    J Clin Endocrinol Metab; 2019 Oct; 104(10):4848-4856. PubMed ID: 30920627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levels of asymmetric dimethylarginine, nitric oxide and lipid peroxidation markers in patients with end-stage renal disease having peritoneal dialysis treatment.
    Göçmen AY; Sahin E; Koçak H; Tuncer M; Gümüşlü S
    Clin Biochem; 2008 Jul; 41(10-11):836-40. PubMed ID: 18457672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.